70 Participants Needed

CCI-001 for Cancer

CA
Overseen ByCharles Allard
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new drug, CCI-001, which targets a protein needed for cell division. It aims to find the safe dose and see how well it works in patients with various advanced cancers.

Will I have to stop taking my current medications?

The trial requires that you stop taking any investigational agents, chemotherapy, immunotherapy, radiotherapy, or molecular targeted agents at least 28 days before enrolling. If you are taking warfarin, you will need to stop, but low-dose or therapeutic heparin is allowed.

Who Is on the Research Team?

JS

Jennifer Spratlin, MD

Principal Investigator

Alberta Health Services, University of Alberta

Are You a Good Fit for This Trial?

Adults with certain types of recurrent or metastatic solid tumors, who have tried other treatments without success or for whom no standard treatment exists. They must be in good health otherwise, with normal organ and marrow function, and not currently receiving other cancer therapies. Women can't be pregnant or nursing, and all participants must agree to use contraception.

Inclusion Criteria

Subject has provided informed consent/assent prior to initiation of any study-specific activities/procedures
Life expectancy of greater than 12 weeks
Normal organ and marrow function as defined below: absolute neutrophil count ≥ 1.5 x 10^9/L, hemoglobin ≥ 90 g/L, platelets ≥ 100 x 10^9/L, total bilirubin ≤ 1.5 X upper limit of normal (ULN), AST(SGOT) and ALT(SGPT) ≤ 2.5 X ULN (≤ 5 X ULN in the presence of liver metastases), Creatinine (Cr) ≤ 1.5 X ULN, Cardiac ejection fraction by echocardiogram must be >50% at baseline, Baseline ECG with QTc ≤ 470msec for females and ≤ 450msec for males, Agree to use adequate contraception for the duration of study participation and for 12 months after receiving the final dose of study drug, Ability and willingness to adhere to study required procedures, Patient must have measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria
See 5 more

Exclusion Criteria

I am on warfarin or low-dose heparin treatments.
Pregnant or nursing women
Human Immunodeficiency Virus (HIV)-positive patients
See 9 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

CCI-001 is administered at escalating doses to determine the maximum tolerated dose

28 days
Cycle 1 Days 1 and 15, Cycle 2 Day 1

Dose Expansion

Patients with specific tumour types are treated at the recommended dose determined during dose escalation

28 days
Cycle 1 Days 1 and 15, Cycle 2 Day 1

Follow-up

Participants are monitored for safety and effectiveness after treatment

36 months
Imaging every 8 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • CCI-001
Trial Overview CCI-001 is a new drug related to colchicine being tested for safety and effective dosage in patients with specific cancers that are known to respond to similar drugs. This first-in-human trial will also look at how the body processes CCI-001 and its impact on tumor size and patient survival.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Dose Escalation and ExpansionExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

PharmaMatrix Holdings Ltd

Lead Sponsor

Trials
1
Recruited
70+

University of Alberta

Collaborator

Trials
957
Recruited
437,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security